XOMA Royalty Corporation's Commitment to Investors
XOMA Royalty Corporation has always placed a high value on its investors. This is evident in the recent action taken by its Board of Directors, as the company has announced cash dividends for its preferred stockholders, specifically for the Series A and Series B Cumulative Preferred Stocks.
Details of the Preferred Stock Dividends
If you're a holder of the 8.625% Series A Cumulative Perpetual Preferred Stock, you'll receive a cash dividend of $0.53906 per share. On the other hand, those with the 8.375% Series B Cumulative Perpetual Preferred Stock will get $0.52344 per depositary share. These dividends showcase the company’s solid commitment to its shareholders and highlight its financial strength.
Important Dates for Stockholders
The dividends are anticipated to be issued on or around October 15, with the record date set for October 3. Shareholders should verify their ownership records to ensure they receive these dividends without delay. This initiative provides financial benefits to investors, reinforcing XOMA's commitment to enhancing shareholder value.
Understanding XOMA Royalty’s Business Model
XOMA Royalty distinguishes itself in the biotechnology sector as a prominent royalty aggregator. The company strategically acquires future economic rights related to promising pre-commercial therapeutic candidates and existing commercial products licensed to various biotech and pharmaceutical firms. This strategic positioning enables the company to offer non-dilutive funding to sellers, fostering the development of innovative drugs while expanding its asset portfolio.
Diverse Portfolio of Assets
Currently, XOMA boasts an impressive portfolio with over 70 unique assets. Each of these assets represents a right to receive potential future income tied to the advancement of therapeutics. This approach not only aids in funding drug development but also enhances XOMA's strategic asset holdings.
Commercial Assets Overview
Among the many assets in XOMA Royalty's expansive portfolio, several commercial products stand out, such as VABYSMO (faricimab-svoa) and IXINITY (coagulation factor IX). Each of these products signifies a promising market potential, thereby solidifying XOMA's position in the industry as an innovative player.
Investor Relations and Contact Information
XOMA Royalty prioritizes transparency and accessibility regarding its investors. For questions, shareholders can get in touch with Juliane Snowden, the Investor Contact, at +1 646-438-9754 or via email. This open communication reflects the company’s commitment to its shareholders.
Frequently Asked Questions
What are the announced cash dividends from XOMA Royalty?
The announced cash dividends are $0.53906 per share for Series A holders and $0.52344 per depositary share for Series B holders.
When will the dividends be paid out?
The expected payout date for the dividends is around October 15, 2024, with a record date set for October 3, 2024.
What is the primary focus of XOMA Royalty?
XOMA Royalty focuses on acquiring royalty rights from biotech companies, providing them with funding while securing economic rights tied to future therapeutic developments.
How many assets does XOMA Royalty currently have?
XOMA Royalty currently has over 70 assets in its portfolio, maintaining a diverse and promising array of economic rights.
Who can investors contact for inquiries?
Investors can reach out to Juliane Snowden at XOMA Royalty Corporation through the provided phone number or email for any questions or concerns.
